Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 March 2023 | Story Chelepe Mocwana | Photo Grand Epic Photography
Chelepe Mocwana
Chelepe Mocwana serves as the Senior Gender Officer in the Gender Equality and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice on the South Campus of the University of the Free State

Opinion article by Chelepe Mocwana, Senior Officer in the University of the Free State Unit for Institutional Change and Social Justice, Gender Equality and Anti-Discrimination Office.
Gender-Based Violence Challenges Facing Men and Young Boys

Men in South Africa and male students at higher education institutions (HEIs) are faced with the challenge of the social construction of what constitutes a ‘man’. This difficulty is rooted in social norms that are embedded in hetero-patriarchal social systems and beliefs. The manifestation of these beliefs is projected in social realities that are configured within power structures. The scourge of gender-based violence and femicide against women and girls, gender and sexual minorities, is a playout of power dynamics that enable the perpetrator to violate their subject. This form of violence is often perpetuated by men against women or gender and sexual minorities. This is exacerbated and compounded by several issues. 

This includes poverty, socialisation, heteronormativity, political history, mental health, unhealthy sexual practices, and toxic masculinities. Men – especially young men – find themselves without a safe space to express themselves about the challenges they face in society today. Other than men feeling that they have no space to engage, there seems to be a general resistance among men to achieve gender equity and partner with women(x) to eradicate gender-based violence. Some of the resistance is due to the socialisation of men. These are behaviours and cultures that men have adopted over time, normalised, and end up accepting as norms and acceptable behaviour. Men today are faced with the challenge of identity and manhood. 

This begs the question. What does it constitute to be a ‘man’ in this time and age? Issues of manhood and identity among young men today are complex and multifaceted. Historical, cultural, and social factors have played a role in shaping these concepts. In African societies, rituals play a major role in forming our identity and manhood. Some of the narratives around these rituals have led to toxic masculinities and related practices formed by men. Globalisation and social media have influenced men’s views on manhood; therefore, a concerted effort is needed to focus on establishing an identity and manhood that is relevant and applicable to the Global South. 

Why Positive Masculinities

Men must find a space to look at their masculinity again. Therefore, we submit that positive masculinity programmes must be promoted as men engage. The objective of such programmes is to promote healthy and constructive expressions of masculinity. Masculinity that makes men comfortable to express their emotions and to be vulnerable. Spaces where they can engage without being judged when they express themselves. Masculinity that are based on values of respect, empathy, responsibility, and emotional intelligence. Men must challenge harmful gender norms and stereotypes, harmful cultural and social norms that perpetuate toxic and violent expressions of masculinity, gender-based violence, and homophobia, and start to promote more inclusive and equitable social norms.

Men are needed who will empower boys and men. Positive masculinity aims to empower men to become positive role models and leaders in their communities. This involves promoting a sense of responsibility and accountability and encouraging men to use their influence to promote positive social change. Ultimately, the objectives of positive masculinity are to promote a more inclusive, equitable, and just society, where individuals of all genders can thrive and reach their full potential. Accountability entails having awareness and acknowledgment of the power and privilege that comes with patriarchy and male privilege; robustly engaging with institutional policies, procedures, and culture to achieve gender equity; respecting and promoting women’s leadership in the gender space and society in general, and continued cooperation with women and gender activists.

Going into the future

It is time for men to speak up and stop being bystanders and onlookers. It is through the promotion of positive and healthy expressions of masculinity that the scourge of gender-based violence can be eliminated. We will achieve equity when we strive to put women, girls, LGBTQI people, and the most marginalised communities at the centre of our awareness and advocacy efforts. No one should be left behind. Men must be partners in eliminating gender-based violence. Men should listen and take women and children seriously; protect women and children and keep them safe; help them to know their rights to be free from violence and abuse; and choose the man they want to be and/or become.




News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept